"This suggests that to block remaining AR growth signaling a novel (i.e., ''bulky"") antiandrogen may need to be added to the dutasteride-androgen ablation combination (45)."
"We are developing such novel monofunctional and bifunctional ''bulky""antiandrogens for such combinatorial AR-targeted therapy."